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ABSTRACT 
 
MALLORY MAIER: Synthesis of Difluoromethyl and Monofluoromethyl Ketones for 
Biological Evaluation at the GABAB Receptor 
(Under the direction of David A. Colby) 
 
The central nervous system communicates using neurotransmitters. Most are 
excitatory neurotransmitters, such as acetylcholine, dopamine, and serotonin, but 𝛾-
aminobutyric acid (GABA) is the primary inhibitory neurotransmitter. There are two 
main types of GABA receptors. The GABAa receptors are ion channels and are targeted 
by many drugs. However, there is a specific interest in developing compounds to interact 
with GABAB receptors due to potential use as addiction treatments. There is currently 
only one FDA approved drug on the market, a muscle relaxer called baclofen, that 
selectively binds to GABAB receptors.  The goal of this project was to synthesize 
fluorinated compounds to be evaluated at the GABAB receptor. The incorporation of 
fluorine into organic molecules is becoming increasingly important in the pharmaceutical 
industry. Specifically, fluorinated ketones are an important functional group in medicinal 
chemistry, but existing methods to synthesize this functional group are low yielding. A 
new method has been developed to access difluoromethyl ketones through the release of 
trifluoracetate, and some of these molecules have been shown to serve as agonists of the 
GABAB receptor. My project is the modification of this method to generate 
monofluoromethyl ketones to be submitted for biological evaluation at the GABAB 
receptor.  
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1. Introduction 
 
1.1 Communication in the Central Nervous System 
Neurons, the functional cells of the central nervous system (CNS), communicate 
through impulses that release neurotransmitters resulting in either the excitation or 
inhibition of the post-synaptic cell. Neurons consist of three primary parts: the cell 
body, dendrites, and the axon. These structures form synapses with other neurons or 
receptors during neurotransmission. Dendrites are short arms on the nerve cell that 
conduct information toward the cell body. The axon extends from the cell body, and 
the terminal end forms a synapse with other neurons or receptor cells. The axon 
conducts nerve impulses from the cell body, called action potentials, to the terminal 
end. 
When the action potential reaches the terminus of the axon, the neuron 
communicates with the postsynaptic cell through either an electrical or a chemical 
signal. Chemical synapses are most commonly found in the CNS. When the action 
potential reaches the terminal of the axon, it signals the release of chemical 
messengers called neurotransmitters. Neurotransmitters are released from the axon 
into the synapse, and they bind to their receptors on the membrane of the postsynaptic 
cell.  
Neurotransmitters are synthesized and stored in the axon terminal in synaptic 
vesicles. When the action potential reaches the terminal, it causes the 
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vesicles to move to the membrane and release the neurotransmitters into the 
synapse. There are various physiological processes in place to remove the 
neurotransmitters from the synapse to maintain precise control of neural transmission. 
These processes include reuptake of the neurotransmitter by the axon, metabolism of 
the neurotransmitter, or diffusion into intercellular fluid resulting in decreased 
concentration. 
There are two types of chemical synapses: excitatory and inhibitory. In an 
excitatory synapse, when the neurotransmitter binds to its receptor on the 
postsynaptic membrane, it results in the depolarization of the postsynaptic membrane 
resulting in the continuation of an action potential. The binding of neurotransmitters 
in an inhibitory synapse reduces the postsynaptic cell’s ability to generate an action 
potential. This effect is generally accomplished by hyperpolarizing the postsynaptic 
membrane, making it more permeable to potassium and/or chloride ions, and less 
likely to depolarize.    
1.2 GABA 
Most neurotransmitters in the CNS are excitatory. The primary inhibitory 
neurotransmitter in the CNS is -aminobutyric acid (GABA). Its major roles are to 
regulate the excitation of neurons as well as regulate the release of other 
neurotransmitters.2 There are two major types of GABA receptors that determine the 
actions of GABA: GABAA and GABAB. GABA receptors are a long-standing target 
in the pharmaceutical industry. 
 
 
 3 
1.2.1 GABAA Receptors 
GABAA receptors are pentamers consisting of two identical  
subunits, two identical  subunits and one “other” subunit assembled 
around a central pore. Sixteen subunits have been identified that make up 
GABAA receptors. The receptors are ligand-gated chloride-ion channels 
that suppress excitation in neurons.3 When GABA binds to the GABAA 
receptor, it increases the cells permeability to chloride which reduces the 
cells ability to generate an action potential.4 
GABAA receptors are the most therapeutically targeted GABA 
receptor. There are three major classes of pharmaceuticals that target 
GABAA receptors: barbituates, benzodiapepines, and non-
benzodiazepines.5 These drugs treat various disease states including 
anxiety, insomnia, seizures and muscle spasms.  
1.2.2 GABAB Receptors 
GABAB receptors are heterodimeric, G-protein coupled receptors. 
The dimer is made up of GABAB1, which contains the GABA binding 
regions, and GABAB2, which activates the G-protein.6 These receptors 
inhibit the release of several neurotransmitters including acetylcholine, 
serotonin, dopamine, and noradrenaline through G-protein-dependent 
inhibition of voltage-gated calcium channels.7 They can also reduce 
neuronal excitation through activation of G-protein regulated potassium 
channels, and regulate intracellular signaling through inhibition of 
adenylyl cyclase ativity.7,8 
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GABAB receptors can be linked to the pathophysiology of many 
CNS diseases and disorders such as anxiety, depression, autism spectrum 
disorders, stroke, drug addiction, Huntington’s disease, Parkinson’s 
disease and Alzheimer’s disease. They can also be linked to muscle 
spasticity disorders, pain and gastroesophageal reflux disease (GERD).3 
Unlike GABAA receptors, there are few pharmaceuticals that target 
GABAB receptors. Implications of targeting the GABAB receptor include 
treatment of anxiety, mood disorders, and addiction to alcohol, cocaine, 
heroin, and nicotine. There remains a great deal of potential in the 
pharmaceutical industry to create drugs that target GABAB receptors.
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1.3 Baclofen and Other GABAB Agonists 
Currently, baclofen, a muscle relaxant, is the only FDA approved drug that 
targets the GABAB receptor.3 The structure of GABA is imbedded in the structure 
of baclofen (Figure 1). Baclofen is used primarily to treat muscle spasms in 
patients with multiple sclerosis or spinal cord injuries. However, baclofen has 
been shown to be effective in off-label treatment and possible treatment of various 
ailments caused in part by pathogenesis of the GABAB receptor pathway, such as 
GERD9, nicotine addiction, and post-traumatic stress disorder10. Despite its 
exclusivity as the only FDA approved GABAB agonist drug, balcofen is far from 
ideal. Baclofen has low penetration into the brain, a narrow therapeutic window, 
short duration of action and a rapid tolerance.11,12 The development of GABAB 
agonists that could overcome these barriers would be a substantial improvement 
over baclofen. 
Previous research has shown that making even subtle changes to the 
structure of baclofen can produce antagonists, eliminate activity at the GABAB 
receptor altogether, or even cause the compound to interact with other GABA 
receptors.3 Baclofen derivatives with structural modifications at the 3-position are 
GABAB agonists.2 For example, 3-aminopropyl phosphinic acid has been 
demonstrated to be a potential inhibitor of GERD, muscle relaxant and treatment 
for addiction.13  
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1.4 Fluorine and Medicinal Chemistry 
Incorporation of fluorine into organic compounds has become increasingly 
important in pharmaceuticals. Over the past several decades, 5–15% of the total 
number of new drugs launched worldwide were fluorinated.14 Fluorine is the most 
electronegative element which gives it certain inherent properties. Incorporating 
fluorine into drug molecules affects the pKa of the drug and can influence certain 
characteristics such as solubility, permeability and protein binding of the drug.15 
These characteristics, in turn, affect the absorption, distribution, metabolism and 
elimination of the drug. There are many examples of molecules where fluorine 
effectively replaced hydrogen or oxygen and maintained comparable activities at 
the site of action for the drug.14 
Fluorine increases the permeability of a drug, which means it is more able 
to pass through a cell membrane. As the lipophilicity of a drug increases, 
likewise, the permeability of the drug increases.15 The lipophilicity of drugs is 
measured and reported as log P values, with a lower log P value being associated 
with higher lipophilicity.15 Mono- and di-fluorination of molecules have been 
shown to result in significant reductions of log P values for drugs.15 By increasing 
permeability of a drug, it simultaneously increases the bioavailability of the drug. 
Figure 1 Structures of GABA and baclofen 
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This improvement is of great importance when developing new drugs, especially 
those that must cross the blood-brain barrier.  
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2. Results and Discussion 
 
2.1 Synthesis of Difluoromethyl Ketones 
While there is not much data on the structure of the GABAB receptor, it is known 
that two key active-site residues include Ser246 and Asp471. These residues have 
critical interactions with baclofen and GABA.16 The carboxylate of baclofen interacts 
with the serine residue of the GABAB receptor, which led researchers to believe that 
α-fluorinated ketones might interact similarly due to their ability to form hemiketals 
with serine residues in an active site and serve as surrogates for carboxylic acids and 
phosphinic acids.2   
 Difluoromethyl ketones were synthesized because of the ketone’s ability to revert 
to a gem diol in water (Figure 2) which increases its solubility and affords a 
tetrahedral shape, which can enable activity as a transition state mimic.1 The 
difluoromethyl-starting material was synthesized from (Z)-4,4,4-trifluoro-3-hydroxy-
1-(naphthalen-2-yl)but-2-en-1-one and selectfluor under anhydrous conditions (see 
experimental details). A novel method has been discovered that was used to assemble 
the difluoromethyl ketones by aldol reactions with difluoroenolates following the 
release of trifluoroacetate in the presence of triethylamine (Figure 3).17 Once 
triflouroacetate is released, the aldol reaction is rapid, resulting in the enolate 
attacking the electrophilic carbon of the aldehyde (Figure 3). Following an aqueous 
workup, the desired difluoromethyl ketone is obtained. 
 
Figure 2 Ketone reverts to gem diol in presence of water 
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Unlike many other routes for fluorochemical synthesis, this approach yields 
difluoromethyl ketones in three synthetic steps with a high yield. The method is also 
versatile and can be used with many different ketones.2 Using this approach, four 
difluoromethyl ketones were synthesized to reproduce reported procedures in the 
literature, as well as to learn the methods and techniques of synthesizing these 
compounds (Figure 4). Each compound was obtained in good yield and purified by 
silica flash chromatography. The reaction with cyclohexylcarbaldehyde required a 
lower temperature to achieve an acceptable yield. Each of these compounds were 
submitted for biological evaluation. 
2.2 Synthesis of Monofluoromethyl Ketones 
It is reported in the literature that difluoromethyl ketones show activity at the 
GABAB receptor.2 The goal of this project was to find out what, if any, activity 
monofluoromethyl ketones have at the GABAB receptor. Another goal was to 
compare how the activity of monofluoromethyl ketones compare to the reported 
activity of difluoromethyl ketones. 
The general synthesis of monofluoromethyl ketones is very similar to that of 
difluoromethyl ketones, with one key difference. The starting material was 
Figure 3 Difluoromethyl ketone from trifluoroacetate release and aldol addition 
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synthesized from reacting (Z)-4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en-
1-one with selectfluor in the presence of water, which lead to monofluorination of the 
compound (Figure 5). The mechanisms and reaction conditions involving 
trifluoroacetate release and the aldol additions remained the same. The same four 
aldehydes used in the difluoromethyl ketones syntheses were used in the 
monofluoromethyl ketone syntheses (Figure 6). 
 
2.3 Identification and Purification of Difluoromethyl Ketones and Monofluoromethyl 
Ketones 
Two primary techniques were used to identify compounds in the synthesis of both 
the difluoromethyl ketones and the monofluoromethyl ketones: thin layer 
chromatography (TLC) and nuclear magnetic resonance spectroscopy (NMR). TLC 
Figure 4 Synthesis of difluoromethyl ketones 14 
Figure 5 Monofluorination of starting material 
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was used to monitor the progress of the reactions. The difluoromethyl ketones were 
synthesized at a rapid rate and leaving behind very little starting material. The  
monofluoromethyl ketones, synthesized under analogous conditions, resulted in much 
lower yields compared to their difluoro-counterparts. TLC was used to monitor the 
progress of the reactions. It was later discovered that the loss of product occurred 
during the transfer of the products from one container to another.  
TLC was also used to optimize solvent systems for the purification of the 
products using flash column chromatography, as well as to assist in collection of the 
products. The solvents used to purify the difluoromethyl ketones, as reported in the 
literature, resulted in the successful separation and purification of compounds at 
relatively high yields. When trying to duplicate purification procedures for the 
monofluoromethyl ketones, separation was not ideal. The solvent systems had to be 
optimized for each monofluormethyl compound based on the polarity of the 
compound and the starting materials (see experimental details).  
Figure 6 Synthesis of monofluoromethyl ketones 58 
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Once the compounds had been purified using flash column chromatography, 
NMR data was analyzed to confirm the purity of the compound. Proton NMR was 
used to determine if any non-fluorinated starting materials, or other impurities, 
remained with the product. Impurities contaminating the desired compounds could 
have lead to inaccurate results in biological testing of the activity of the compound at 
the GABAB receptor. Fluorine NMR was used to verify that the starting material was 
not present, and that the correct number of fluorines were present on the desired 
compound. This data was especially important for the monofluoromethyl ketones to 
make sure that the difluoromethyl ketones were not present, because difluoromethyl 
ketones could alter the results of biological testing. Since it is already known that 
difluoromethyl ketones are active at the GABAB receptor, a mixture of 
difluoromethyl and monoflouomethyl ketones could lead to false biological activity 
results.  
2.4 Biological Evaluation at the GABAB Receptor 
Biological evaluation of GABA, baclofen, and difluoromethyl ketones was 
performed to measure selectivity and potency at the GABAA and GABAB receptors, 
and the values were reported (Table 1).2 GABAB agonist activity was measured using 
a cell line expressing subunits of the human GABAB receptor that when activated, 
inhibits the production of cAMP.2 In the assay, forskolin, an activator of adenylyl 
cyclase, was used to stimulate cAMP production. Inhibition of forskolin-stimulated 
accumulation of cAMP was measured and reported.2 
Baclofen and GABA were used as positive controls in the assay, and the results 
were comparable to other reported EC50 values in the literature.2 The lower the EC50 
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value, the more potent the compound is at the receptor. Based on the values reported 
in Table 1, the difluoromethyl ketones synthesized show significant activity and 
selectivity at the GABAB receptor. Although compound 9 was not synthesized in this 
project, it shows the greatest potency at the GABAB receptor. 
The goal of this project was to determine how the biologic activity of 
monofluoromethyl ketones compares to that of baclofen, GABA and the 
difluoromethyl ketones. Compound 10 (Table 1), was synthesized and tested by 
another member of David Colby’s lab at the University of Mississippi, and it is 
reported that it showed a greater potency at the GABAB receptor than its difluoro-
analog. These data drive the need to determine whether all monofluoromethyl ketones 
would show greater potency at the GABAB receptor over difluoromethyl ketones. 
Compounds 5–8 have been submitted for biological evaluation, but no data has been 
received. It is not known why the monofluorinated compound 10 exhibits greater 
activity than the difluorinated compound 9. 
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Table 1 Biologic activity at the GABAB receptor 
Compound GABAB EC50 (M)a GABAA EC50 (M)a 
GABA 0.53  0.33 >100 b 
Baclofen 1.7  0.10 b 2.30  0.59 b 
1  
61.8  3.01 b >100 b 
2  
53.5  1.76 b >100 b 
3  
99.3  3.78 b >100 b 
4  
66.9  1.19 b >100 b 
9  
24.9  1.30 b >100 b 
10  
12.2 nd 
5  
nd nd 
6  
nd nd 
7  
nd nd 
8  
nd nd 
                                                 
a Values are given with standard error. 
b Source: Han, C.; Salyer, A. E.; Kim, E. H.; Jiang, X.; Jarrad, R. E.; Powers, M. S.; Kirchhoff, A. 
M.; Salvador, T. K.; Chester, J. A.; Hockerman, G. H.; Colby, D. A. Evaluation of 
Difluoromethyl ketones as Agonists of the 𝛾-Aminobutyric Acid Type B Receeptor. Med. Chem. 
2013, 56, 2456–2465 
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3. Conclusion 
 In summary, eight fluorinated compounds were synthesized to be evaluated at the 
GABA receptors. Four difluoromethyl ketones were synthesized using a novel method 
involving the release of trifluoroacetate to extend the scope of the published procedure. 
The compounds were purified via flash column chromatography and the purity of the 
compounds was evaluated using 1H NMR and 19F NMR. Additionally, four 
monofluoromethyl ketones were synthesized using similar techniques to be biologically 
evaluated at the GABAB receptor. The goal of the project was to determine if 
monofluoromethyl ketones have a greater potency than difluoromethyl ketones at the 
GABAB receptor. Samples of monofluormethyl ketones were sent for biological testing, 
but no results have been received at this time. 
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4. Experimental Details 
 
2,2,4,4,4-Pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one. A mixture of 
(Z)-4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one (0.500 g, 1.88 mmol) 
and acetonitrile (12.5 mL) was treated with selectfluor (1.66 g, 4.70 mmol) at rt under 
argon. After 20 h, the reaction was diluted with ethyl acetate (125 mL) and filtered 
through Celite. The residue was concentrated in vacuo, dissolved in dichloromethane (50 
mL) and washed with water (50 mL). The aqueous layer was extracted with 
dichloromethane (50 mL). The organics were dried over Na2SO4 and concentrated under 
reduced pressure. The solid product was afforded in 92% yield: 1H NMR (500 MHz, 
CDCl3) δ 8.74 (s, 1H), 8.06 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.7 
Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.70 (t, J = 7.0 Hz, 1H), 7.61 (t, J = 7.1 Hz, 1H), 4.74 
(s, 2H). 
 
2,2-Difluoro-3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)propan-1-one, 1. A 
mixture of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 
0.2 mmol), p-anisaldehyde (38 L, 0.31 mmol), and LiBr (41 mg, 0.47 mmol) in THF (1 
mL) was treated with triethylamine (22 L, 0.16 mmol) dropwise. The reaction was 
stirred at rt for 10 min, and was quenched with saturated aqueous NH4Cl (3 mL). The 
mixture was extracted with ethyl acetate (3 mL  5). The organics were dried over 
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (3.5:1.5 
hexanes/ethyl acetate) afforded the product as a solid in 77% yield: 1H NMR (500 MHz, 
CDCl3) δ 8.62 (s, 1H), 8.05 (d, J = 9.1 Hz, 1H), 7.97 – 7.84 (m, 2H), 7.65 (t, J = 7.0 Hz, 
1H), 7.57 (t, J = 7.4 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 5.39 (dd, 
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J = 18.0, 5.9 Hz, 1H), 3.81 (s, 3H), 2.99 (s, 1H). 
 
3-Cyclohexyl-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)propan-1-one, 2. A mixture 
of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 
mmol), cyclohexanecarbaldehyde (38 L, 0.31 mmol), and LiBr (47 mg, 0.55 mmol) in 
THF (1 mL) was treated with triethylamine (86 L, 0.62 mmol) dropwise. The reaction 
was stirred at 78C for 30 min, and was quenched with saturated aqueous NH4Cl (3 
mL). The mixture was extracted with ethyl acetate (3 mL  5). The organics were dried 
over Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (9:1 
hexanes/ethyl acetate) afforded the product as a solid in 84% yield: 1H NMR (500 MHz, 
CDCl3) δ 8.70 (s, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.90 (dd, J = 
12.2, 8.5 Hz, 3H), 7.65 (dt, J = 8.2, 1.2 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 4.13 (dq, J = 
19.6, 6.1 Hz, 1H), 2.43 (d, J = 6.7 Hz, 1H), 2.12–1.53 (m, 6H), 1.47–1.16 (m, 5H). 
 
(4E,6E)-2,2-Difluoro-3-hydroxy-1-(naphthalen-2-yl)octa-4,6-dien-1-one, 3. A mixture 
of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 
mmol), (2E,4E)-hexa-2,4-dienal (34 L, 0.31 mmol), and LiBr (47 mg, 0.55 mmol) in 
THF (1 mL) was treated with triethylamine (22 L, 0.16 mmol) dropwise. The reaction 
was stirred at rt for 10 min, and was quenched with saturated aqueous NH4Cl (3 mL). The 
mixture was extracted with ethyl acetate (3 mL  5). The organics were dried over 
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (9:1 
hexanes/ethyl acetate) afforded the product as a solid in 55% yield: 1H NMR (500 MHz, 
CDCl3) δ 8.71 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.89 (dd, J = 
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11.0, 8.6 Hz, 2H), 7.65 (t, J = 7.1 Hz, 1H), 7.57 (t, J = 7.9 Hz, 1H), 6.45 (dd, J = 15.3, 
10.5 Hz, 1H), 6.21 – 5.97 (m, 1H), 5.90 – 5.76 (m, 1H), 5.72 (dd, J = 15.4, 6.9 Hz, 1H), 
4.85 (dt, J = 14.7, 6.9 Hz, 1H), 2.74 (s, 1H), 1.78 (d, J = 6.5 Hz, 3H). 
 
(E)-2,2-Difluoro-3-hydroxy-1-(naphthalen-2-yl)oct-4-en-1-one, 4. A mixture of 
2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.3 mmol), 
(E)-hex-2-enal (37 L, 0.31 mmol), and LiBr (47 mg, 0.55 mmol) in THF (1 mL) was 
treated with triethylamine (22 L, 0.16 mmol) dropwise. The reaction was stirred at rt for 
10 min, and was quenched with saturated aqueous NH4Cl (3 mL). The mixture was 
extracted with ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and 
concentrated under reduced pressure. SiO2 flash chromatography (9:1 hexanes/ethyl 
acetate) afforded the product as a solid in 45% yield: 1H NMR (500 MHz, CDCl3) δ 8.71 
(s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.90 (dd, J = 11.9, 8.5 Hz, 2H), 
7.65 (t, J = 7.5 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 5.96 (dt, J = 14.2, 6.7 Hz, 1H), 5.66 (dd, 
J = 15.5, 6.9 Hz, 1H), 4.78 (dq, J = 13.0, 6.5 Hz, 1H), 2.61 (d, J = 5.6 Hz, 1H), 2.10 (q, J 
= 7.0 Hz, 2H), 1.43 (q, J = 7.3 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
 
2,4,4,4-Tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one. A mixture of (Z)-
4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one (0.500 g, 1.88 mmol), water 
(6 mL) and acetonitrile (6 mL) was treated with selectfluor (0.665 g, 1.88 mmol) at rt 
under air. After 18 h, the residue was washed with water (50 mL). Saturated aqueous 
NaCl (10 mL) was added to the mixture and the product was extracted with 
dichloromethane (10 mL  5). The combined organics were dried over Na2SO4 and 
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concentrated under reduced pressure. The solid product was afforded in 88% yield: 1H 
NMR (500 MHz, CDCl3) δ 8.61 (s, 1H), 8.02 (dd, J = 7.7, 4.5 Hz, 2H), 7.92 (dd, J = 
14.2, 8.4 Hz, 2H), 7.68 (t, J = 8.1 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 5.87 (d, J = 47.8 Hz, 
1H), 4.90 (s, 1H), 4.55 (s, 1H); 19F NMR (376 MHz, CDCl3) δ –83.9 (d, J = 11.5 Hz, 3F), 
–194.6 (dq, J = 47.7, 11.2 Hz, 1F). 
 
2-Fluoro-3-hydroxy-3-(4-methoxyphenyl)-1-(naphthalen-2-yl)propan-1-one, 5. A 
mixture of 2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 
mmol), cyclohexanecarbaldehyde (40 L, 0.33 mmol), and LiBr (72 mg, 0.82 mmol) in 
THF (1 mL) was treated with triethylamine (27 L, 0.20 mmol) dropwise. The reaction 
was stirred at rt for 30 min, and was quenched with saturated aqueous NH4Cl (3 mL). The 
mixture was extracted with ethyl acetate (3 mL  5). The organics were dried over 
Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (3.5:1.5 
hexanes/ethyl acetate) afforded the product as an inseparable mixture of diastereomers 
(dr = 1.78:1) in 23% yield: 1H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 15.2 Hz, 1H), 7.94 
(dd, J = 14.1, 9.2 Hz, 2H), 7.91–7.85 (m, 2H), 7.63 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 7.4 
Hz, 1H), 7.38 (dd, J = 8.6, 3.9 Hz, 2H), 6.87 (dd, J = 12.4, 8.7 Hz, 2H), 5.85–5.58 (m, 
1H), 5.31 (d, J = 22.5 Hz, 1H), 3.76 (d, J = 14.0 Hz, 3H), 2.98 (s, 1H); 19F NMR (376 
MHz, CDCl3) δ –188.9– –189.9* (m, 1F), –195.9 (dd, J = 48.4, 21.3 Hz, 1F). *Denotes 
minor diastereomer. 
 
3-Cyclohexyl-2-fluoro-3-hydroxy-1-(naphthalen-2-yl)propan-1-one, 6. A mixture of 
2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 mmol), p-
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anisaldehyde (40 L, 0.3 mmol), and LiBr (50 mg, 0.6 mmol) in THF (1 mL) was treated 
with triethylamine (92 L, 0.66 mmol) dropwise. The reaction was stirred at rt for 10 
min, and was quenched with saturated aqueous NH4Cl (3 mL). The mixture was extracted 
with ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and concentrated 
under reduced pressure. SiO2 flash chromatography (4:1 dichloromethane/hexanes) 
afforded the product as a solid in 57% yield: 1H NMR (500 MHz, CDCl3) δ 8.58 (s, 1H), 
8.03 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.90 (dd, J = 11.6, 8.5 Hz, 2H), 7.63 (t, 
J = 6.9 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 5.60 (dd, J = 47.7, 7.0 Hz, 1H), 4.06 (s, 1H), 
2.46 (s, 1H), 1.97–1.54 (m, 6H), 1.46–1.11 (m, 5H); 19F NMR (376 MHz, CDCl3) δ –
190.7 (dd, J = 47.8, 9.8 Hz, 1F). 
 
(4E,6E)-2-Fluoro-3-hydroxy-1-(naphthalen-2-yl)octa-4,6-dien-1-one, 7. A mixture of 
2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 mmol), 
(2E,4E)-hexa-2,4-dienal (38 L, 0.33 mmol), and LiBr (50 mg, 0.6 mmol) in THF (1 mL) 
was treated with triethylamine (23 L, 0.16 mmol) dropwise. The reaction was stirred at 
rt for 30 min, and was quenched with saturated aqueous NH4Cl (3 mL). The mixture was 
extracted with ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and 
concentrated under reduced pressure. SiO2 flash chromatography (9:1 hexanes/ethyl 
acetate) afforded the product as an inseparable mixture of diastereomers (dr = 15:1) in 
40% yield: 1H NMR (500 MHz, CDCl3) δ 8.55 (s, 1H), 7.99 (t, J = 8.8 Hz, 2H), 7.95 – 
7.84 (m, 2H), 7.63 (t, J = 8.0, 6.9 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 6.36 (dd, J = 15.5, 
10.3 Hz, 1H), 6.03 (t, J = 12.9 Hz, 1H), 5.86–5.47 (m, 3H), 4.78 (d, J = 21.1 Hz, 1H), 
2.36 (s, 1H), 1.75 (d, J = 6.6 Hz, 3H); 19F NMR (376 MHz, CDCl3) δ –194.2* (dd, J = 
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48.6, 15.0 Hz, 1F), –198.5 (dd, J = 48.3, 21.7 Hz, 1F). *Denotes minor diastereomer. 
 
(E)-2-Fluoro-3-hydroxy-1-(naphthalen-2-yl)oct-4-en-1-one, 8. A mixture of 2,4,4,4-
tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (50 mg, 0.2 mmol), (E)-hex-2-
enal (38 L, 0.33 mmol), and LiBr (50 mg, 0.6 mmol) in THF (1 mL) was treated with 
triethylamine (23 L, 0.16 mmol) dropwise. The reaction was stirred at rt for 30 min, and 
was quenched with saturated aqueous NH4Cl (3 mL). The mixture was extracted with 
ethyl acetate (3 mL  5). The organics were dried over Na2SO4 and concentrated under 
reduced pressure. SiO2 flash chromatography (4:1:0.5 dichloromethane/hexanes/ethyl 
acetate) afforded the product as an inseparable mixture of diastereomers (dr = 1.6:1) in 
83% yield: 1H NMR (500 MHz, CDCl3) δ 8.54 (d, J = 5.6 Hz, 1H), 7.99 (t, J = 8.4 Hz, 
2H), 7.95–7.85 (m, 2H), 7.64 (t, J = 7.5 Hz, 1H), 7.60–7.54 (m, 1H), 5.94–5.49 (m, 3H), 
4.71 (dd, J = 16.9, 6.7 Hz, 1H), 2.46 (s, 1H), 2.00 (d, J = 6.8 Hz, 2H), 1.40–1.30 (m, 2H), 
0.84 (td, J = 7.4, 3.6 Hz, 3H); 19F NMR (376 MHz, CDCl3) δ –195.5 (dd, J = 48.4, 16.3 
Hz, 1F), –198.4* (dd, J = 48.5, 21.0 Hz, 1F). *Denotes minor diastereomer. 
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